Secretion of acid sphingomyelinase is affected by its polymorphic signal peptide

Cellular Physiology and Biochemistry

Volumn 34, Issue 4, 2014, Pages 1385-1401

  Rhein, Cosima ^a   Reichel, Martin ^a   Mühle, Christiane ^a   Rotter, Andrea ^a   Schwab, Sibylle G ^a,b   Kornhuber, Johannes ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Acid sphingomyelinase; Ceramide; Coding polymorphisms; Secreted and lysosomal form; Signal peptide; TNF induced secretion

Indexed keywords

SIGNAL PEPTIDE; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME RELEASE; GENOTYPE; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MATURATION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; SECRETION RATE; WILD TYPE; CELL CULTURE; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ALLELES; CELLS, CULTURED; HUMANS; POLYMORPHISM, GENETIC; PROTEIN SORTING SIGNALS; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908619827     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366345     Document Type: Article

References (69)

1. Quintern LE, Weitz G, Nehrkorn H, Tager JM, Schram AW, Sandhoff K: Acid sphingomyelinase from human urine: Purification and characterization. Biochim Biophys Acta 1987;922:323-336.
2. Herr I, Wilhelm D, Böhler T, Angel P, Debatin KM: Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. Embo J 1997;16:6200-6208.
3. Quintans J, Kilkus J, McShan CL, Gottschalk AR, Dawson G: Ceramide mediates the apoptotic response of wehi 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem Biophys Res Commun 1994;202:710-714.
4. Kolesnick RN, Goni FM, Alonso A: Compartmentalization of ceramide signaling: Physical foundations and biological effects. J Cell Physiol 2000;184:285-300.
5. Holopainen JM, Subramanian M, Kinnunen PK: Sphingomyelinase induces lipid microdomain formation in a fluid phosphatidylcholine/sphingomyelin membrane. Biochemistry 1998;37:17562-17570.
6. Nurminen TA, Holopainen JM, Zhao H, Kinnunen PK: Observation of topical catalysis by sphingomyelinase coupled to microspheres. J Am Chem Soc 2002;124:12129-12134.
7. Grassmé H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001;276:20589-20596.
8. Grassmé H, Riethmüller J, Gulbins E: Biological aspects of ceramide-enriched membrane domains. Prog Lipid Res 2007;46:161-170.
9. Carpinteiro A, Dumitru C, Schenck M, Gulbins E: Ceramide-induced cell death in malignant cells. Cancer Lett 2008;264:1-10.
10. Pettus BJ, Chalfant CE, Hannun YA: Sphingolipids in inflammation: Roles and implications. Curr Mol Med 2004;4:405-418.
11. Ogretmen B, Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-616.
12. Spiegel S, Cuvillier O, Edsall LC, Kohama T, Menzeleev R, Olah Z, Olivera A, Pirianov G, Thomas DM, Tu Z, Van Brocklyn JR, Wang F: Sphingosine-1-phosphate in cell growth and cell death. Ann N Y Acad Sci 1998;845:11-18.
13. Spiegel S, Merrill AH Jr: Sphingolipid metabolism and cell growth regulation. FASEB J 1996;10:1388-1397.
14. Schissel SL, Schuchman EH, Williams KJ, Tabas I: Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem 1996;271:18431-18436.
15. Jenkins RW, Canals D, Idkowiak-Baldys J, Simbari F, Roddy P, Perry DM, Kitatani K, Luberto C, Hannun YA: Regulated secretion of acid sphingomyelinase: Implications for selectivity of ceramide formation. J Biol Chem 2010;285:35706-35718.
16. Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I: The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 1998;273:18250-18259.
17. Ferlinz K, Hurwitz R, Vielhaber G, Suzuki K, Sandhoff K: Occurrence of two molecular forms of human acid sphingomyelinase. Biochem J 1994;301:855-862.
18. Hurwitz R, Ferlinz K, Vielhaber G, Moczall H, Sandhoff K: Processing of human acid sphingomyelinase in normal and I-cell fibroblasts. J Biol Chem 1994;269:5440-5445.
19. Bartelsen O, Lansmann S, Nettersheim M, Lemm T, Ferlinz K, Sandhoff K: Expression of recombinant human acid sphingomyelinase in insect sf21 cells: Purification, processing and enzymatic characterization. J Biotechnol 1998;63:29-40.
20. Ferlinz K, Hurwitz R, Moczall H, Lansmann S, Schuchman EH, Sandhoff K: Functional characterization of the n-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. Eur J Biochem 1997;243:511-517.
21. Qiu H, Edmunds T, Baker-Malcolm J, Karey KP, Estes S, Schwarz C, Hughes H, Van Patten SM: Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine. J Biol Chem 2003;278:32744-32752.
22. Lansmann S, Ferlinz K, Hurwitz R, Bartelsen O, Glombitza G, Sandhoff K: Purification of acid sphingomyelinase from human placenta: Characterization and N-terminal sequence. FEBS Lett 1996;399:227-231.
23. Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A, Gold PW, Hirsch E, Williams KJ, Licinio J, Tabas I: Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A 2000;97:8681-8686.
24. Romiti E, Vasta V, Meacci E, Farnararo M, Linke T, Ferlinz K, Sandhoff K, Bruni P: Characterization of sphingomyelinase activity released by thrombin-stimulated platelets. Mol Cell Biochem 2000;205:75-81.
25. Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ, Tabas I: Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998;273:4081-4088.
26. Brady RO, Kanfer JN, Mock MB, Fredrickson DS: The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci U S A 1966;55:366-369.
27. Selzner M, Bielawska A, Morse MA, Rüdiger HA, Sindram D, Hannun YA, Clavien PA: Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001;61:1233-1240.
28. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P, Tettamanti G: Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002;39:105-113.
29. He X, Huang Y, Li B, Gong CX, Schuchman EH: Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 20010;31:398-408.
30. Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E: High activity of acid sphingomyelinase in major depression. J Neural Transm 2005;112:1583-1590.
31. Reichel M, Greiner E, Richter-Schmidinger T, Yedibela O, Tripal P, Jacobi A, Bleich S, Gulbins E, Kornhuber J: Increased acid sphingomyelinase activity in peripheral blood cells of acutely intoxicated patients with alcohol dependence. Alcohol Clin Exp Res 2010;34:46-50.
32. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E: Host defense against pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330.
33. Mikati MA, Zeinieh M, Habib RA, El Hokayem J, Rahmeh A, El Sabban M, Usta J, Dbaibo G: Changes in sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus. Epilepsy Res 2008;81:161-166.
34. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassmé H, Doring G, Gulbins E: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14:382-391.
35. Reichel M, Beck J, Mühle C, Rotter A, Bleich S, Gulbins E, Kornhuber J: Activity of secretory sphingomyelinase is increased in plasma of alcohol-dependent patients. Alcohol Clin Exp Res 2011;35:1852-1859.
36. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
37. Doehner W, Bunck AC, Rauchhaus M, von Haehling S, Brunkhorst FM, Cicoira M, Tschope C, Ponikowski P, Claus RA, Anker SD: Secretory sphingomyelinase is upregulated in chronic heart failure: A second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 2007;28:821-828.
38. Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Losche W, Kinscherf R, Deigner HP: Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J 2005;19:1719-1721.
39. Grammatikos G, Mühle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J, Zeuzem S, Sarrazin C, Pfeilschifter J: Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochim Biophys Acta 2014;1841:1012-1020.
40. Marathe S, Kuriakose G, Williams KJ, Tabas I: Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. Arterioscler Thromb Vasc Biol 1999;19:2648-2658.
41. Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schütze S, Gulbins E, Uhlig S: PAF-mediated pulmonary edema: A new role for acid sphingomyelinase and ceramide. Nat Med 2004;10:155-160.
42. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM: Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005;11:491-498.
43. Rhein C, Naumann J, Mühle C, Zill P, Adli M, Hegerl U, Hiemke C, Mergl R, Möller H-J, Reichel M, Kornhuber J: The acid sphingomyelinase sequence variant p.A487V is not associated with decreased levels of enzymatic activity. JIMD Rep 2013;8:1-6.
44. Dastani Z, Ruel IL, Engert JC, Genest J Jr, Marcil M: Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not contribute to low levels of high-density lipoprotein cholesterol. BMC Med Genet 2007;8:79.
45. Reichel M, Richter-Schmidinger T, Mühle C, Rhein C, Alexopoulos P, Schwab SG, Gulbins E, Kornhuber J: The common acid sphingomyelinase polymorphism G508R is associated with self-reported allergy. Cell Physiol Biochem 2014;34:82-91.
46. Schuchman EH, Levran O, Suchi M, Desnick RJ: An MspI polymorphism in the human acid sphingomyelinase gene (SMPD1). Nucleic Acids Res 1991;19:3160.
47. Wan Q, Schuchman EH: A novel polymorphism in the human acid sphingomyelinase gene due to size variation of the signal peptide region. Biochim Biophys Acta 1995;1270:207-210.
48. Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M, Sidiropoulos C, Rhein C, Lewczuk P, Doerfler A, Kornhuber J: Hippocampal volume differences between healthy young apolipoprotein E e2 and e4 carriers. J Alzheimers Dis 2011;26:207-210.
49. Richter-Schmidinger T, Alexopoulos P, Horn M, Maus S, Reichel M, Rhein C, Lewczuk P, Sidiropoulos C, Kneib T, Perneczky R, Doerfler A, Kornhuber J: Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J Neural Transm 2011;118:249-257.
50. Rhein C, Mühle C, Richter-Schmidinger T, Alexopoulos P, Doerfler A, Kornhuber J: Neuroanatomical correlates of intelligence in healthy young adults: The role of basal ganglia volume. PLOS ONE 2014;9:e93623.
51. Rhein C, Tripal P, Seebahn A, Konrad A, Kramer M, Nagel C, Kemper J, Bode J, Mühle C, Gulbins E, Reichel M, Becker CM, Kornhuber J: Functional implications of novel human acid sphingomyelinase splice variants. PLOS ONE 2012;7:e35467.
52. Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-1169.
53. Kochl R, Alken M, Rutz C, Krause G, Oksche A, Rosenthal W, Schulein R: The signal peptide of the G protein-coupled human endothelin B receptor is necessary for translocation of the N-terminal tail across the endoplasmic reticulum membrane. J Biol Chem 2002;277:16131-16138.
54. von Heijne G: Signal sequences. The limits of variation. J Mol Biol 1985;184:99-105.
55. von Heijne G: Towards a comparative anatomy of N-terminal topogenic protein sequences. J Mol Biol 1986;189:239-242.
56. Martoglio B, Dobberstein B: Signal sequences: More than just greasy peptides. Trends Cell Biol 1998;8:410-415.
57. Hegde RS, Bernstein HD: The surprising complexity of signal sequences. Trends Biochem Sci 2006;31:563-571.
58. Bulbarelli A, Sprocati T, Barberi M, Pedrazzini E, Borgese N: Trafficking of tail-anchored proteins: Transport from the endoplasmic reticulum to the plasma membrane and sorting between surface domains in polarised epithelial cells. J Cell Sci 2002;115:1689-1702.
59. Watson RT, Pessin JE: Transmembrane domain length determines intracellular membrane compartment localization of syntaxins 3, 4, and 5. Am J Physiol Cell Physiol 2001;281:C215-223.
60. Visvikis S, Chan L, Siest G, Drouin P, Boerwinkle E: An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. Hum Genet 1990;84:373-375.
61. Sturley SL, Talmud PJ, Brasseur R, Culbertson MR, Humphries SE, Attie AD: Human apolipoprotein B signal sequence variants confer a secretion-defective phenotype when expressed in yeast. J Biol Chem 1994;269:21670-21675.
62. Xu CF, Tikkanen MJ, Huttunen JK, Pietinen P, Butler R, Humphries S, Talmud P: Apolipoprotein B signal peptide insertion/deletion polymorphism is associated with Ag epitopes and involved in the determination of serum triglyceride levels. J Lipid Res 1990;31:1255-1261.
63. Saha N, Tay JS, Chew LS: Influence of apolipoprotein B signal peptide insertion/deletion polymorphism on serum lipids and apolipoproteins in a chinese population. Clin Genet 1992;41:152-156.
64. Ng TW, Ooi EM, Watts GF, Chan DC, Barrett PH: Genetic determinants of apolipoprotein B-100 kinetics. Curr Opin Lipidol 2010;21:141-147.
65. Halsall DJ, Martensz ND, Luan J, Maison P, Wareham NJ, Hales CN, Byrne CD: A common apolipoprotein B signal peptide polymorphism modifies the relation between plasma non-esterified fatty acids and triglyceride concentration in men. Atherosclerosis 2000;152:9-17.
66. Boekholdt SM, Peters RJ, Fountoulaki K, Kastelein JJ, Sijbrands EJ: Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: A systematic meta-analysis. Hum Genet 2003;113:417-425.
67. Hegde RS: Targeting and beyond: New roles for old signal sequences. Mol Cell 2002;10:697-698.
68. Defour A, Van der Meulen JH, Bhat R, Bigot A, Bashir R, Nagaraju K, Jaiswal JK: Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion. Cell Death Dis 2014;5:e1306.
69. Perrotta C, Bizzozero L, Cazzato D, Morlacchi S, Assi E, Simbari F, Zhang Y, Gulbins E, Bassi MT, Rosa P, Clementi E: Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J Biol Chem 2010;285:40240-40251.